Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Q&A indicates LSA has brought some good new investors

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Jun 21, 2021 12:47pm

117 Views

Post# 33420746

RE:RE:RE:RE:RE:Q&A indicates LSA has brought some good new investors

Like Wino, I asked a commercially oriented question that was ignored. I suspect LSA wanted to keep this one focused on science.

qwerty22 wrote:
That was one thing missing any talk about commercial, comparable companies, ADC market etc

Wino115 wrote: I think we snuffed out your's and JFMs questions -- the 2nd MOA one and the imaging one.
Mine didn't get asked as it was to crass I guess -- what do you think is the commercial opportunity for this platform? and , do you think clinics will use it at the 2L and 3L level if sortilin is expressed enough?

qwerty22 wrote:
I got two Qs asked

Wino115 wrote:

Or JFM Scarlet and QWERTY stuffed the Q&A box.

SPCEO1 wrote: Very scientific questions indicate to me that US based institutions are indeed on this call - a very good sign for LSA's capabilities.